Related references
Note: Only part of the references are listed.Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
J. L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
CLINICAL AND RADIOGRAPHIC OUTCOMES AT 2 YEARS AND THE EFFECT OF TOCILIZUMAB DISCONTINUATION FOLLOWING SUSTAINED REMISSION IN THE SECOND AND THIRD YEAR OF THE ACT-RAY STUDY
T. W. Huizinga et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
Tihamer Orban et al.
DIABETES CARE (2014)
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
Norihiro Nishimoto et al.
MODERN RHEUMATOLOGY (2014)
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
Josef S. Smolen et al.
LANCET (2014)
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
Jacqueline Detert et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis
Maurizio Cutolo et al.
AUTOIMMUNITY REVIEWS (2013)
A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers
Cristina Pomirleanu et al.
CLINICAL RHEUMATOLOGY (2013)
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Josef S. Smolen et al.
LANCET (2013)
Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study
Peter Nash et al.
ARTHRITIS CARE & RESEARCH (2013)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
M. van den Broek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Greater Likelihood of Remission in Rheumatoid Arthritis Patients Treated Earlier in the Disease Course: Results From the Consortium of Rheumatology Researchers of North America Registry
Daniel E. Furst et al.
ARTHRITIS CARE & RESEARCH (2011)
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Progression in early rheumatoid arthritis
Bernard Combe
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2009)
Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study
Gerd R. Burmester et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal - Results from a twelve-month randomized, double-blind, placebo-controlled trial
MA Quinn et al.
ARTHRITIS AND RHEUMATISM (2005)
Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria
J Fransen et al.
RHEUMATOLOGY (2004)
Prognostic markers of radiographic progression in early rheumatoid arthritis
JJ Goronzy et al.
ARTHRITIS AND RHEUMATISM (2004)
Costimulatory blockade in patients with rheumatoid arthritis a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
LW Moreland et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
